Prescription drug · ANDA
Perphenazine NDC 70518-3108
Perphenazine 8 mg/1 · Tablet, Film coated · Oral · REMEDYREPACK INC.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 70518-3108-0 | 70518310800 | 30 TABLET, FILM COATED in 1 BLISTER PACK (70518-3108-0)Marketed from May 28, 2021 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Perphenazine
- Generic name (nonproprietary)
- perphenazine
- Active ingredients
- Perphenazine — 8 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- REMEDYREPACK INC.
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 089685
- Marketing start
- Marketing end
- Other FDA classes
- Phenothiazines (Chemical structure)
- Identifiers
- Product ID 70518-3108_5474c7fd-2125-1e60-e063-6294a90a6ddbSPL ID 5474c7fd-2125-1e60-e063-6294a90a6ddbSPL set ID fc903628-248c-4d12-88b4-a551aeadb4d2RxCUI 198078UNII FTA7XXY4EZ
- Pharmacologic class
- Phenothiazine
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N470518310800followed by a unit qualifier and the quantityPackage 70518-3108-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
INDICATIONS AND USAGE Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation.
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 089685
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Perphenazine | Perphenazine 2 mg/1 | Tablet, Film coatedOral | REMEDYREPACK INC. | 70518-4688 |
| Perphenazine | Perphenazine 2 mg/1 | Tablet, Film coatedOral | Sandoz Inc | 0781-8046 |
| Perphenazine | Perphenazine 4 mg/1 | Tablet, Film coatedOral | Sandoz Inc | 0781-8047 |
| Perphenazine | Perphenazine 8 mg/1 | Tablet, Film coatedOral | Sandoz Inc | 0781-8048 |
| Perphenazine | Perphenazine 16 mg/1 | Tablet, Film coatedOral | Sandoz Inc | 0781-8049 |
| Perphenazine | Perphenazine 4 mg/1 | Tablet, Film coatedOral | REMEDYREPACK INC. | 70518-4112 |